EUCTR2008-000197-20-DE进行中（未招募）不适用
Multi-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety and efficacy of Bimosiamose 5% Cream for the treatment of patients with chronic plaque type psoriasis - Psoriasis POC
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All of the following criteria have to be met for inclusion of a patient with chronic plaque type psoriasis into the study:
- •1.Male patients or postmenopausal female patients with amenorrhea of at least twelve consecutive months duration prior to screening (medical certificate by gynecologist) or sterile female patients with documented hysterectomy or tubal ligation
- •2.PASI score of 5-15 (plaques must not be exclusively over the knees and elbows) and a PGA of = moderate
- •3.At least 18 years of age
- •4.Time and ability to complete the study and comply with instructions
- •5.Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients are to be excluded from the study when one or more of the following conditions are met:
- •1.Active skin infection or other skin conditions that may influence the evaluation of the psoriatic lesions e.g. eczema
- •2.More than 20% Body Surface Area (BSA) affected by psoriasis (excluding palmar or plantar located)
- •3.Use of anti-psoriasis medication or treatments below (except emollients):
- •a.Retinoid, calcipotriene, coal tar or anthralin =14 days prior to Baseline
- •b.Systemic and topical corticosteroids, fumarate, methotrexate, cyclosporine or systemic retinoids, =30 days prior to Baseline
- •c.Prolonged sun exposure =30 days prior to Baseline
- •d.Laser therapy or Photodynamic therapy (or PUVA) =30 days prior to Baseline
- •e.Etanercept, efalizumab, infliximab or adalimumab =90 days prior to Baseline
- •f.Alefacept or IL-12/23 inhibitors =180 days prior to Baseline
- •g.On lithium, antimalarials, beta blockers or ACE inhibitors unless the dose has been stable for 60 days prior to entry and is planned to remain stable during the study
- •4.Clinical study participation with any investigational drug less than 90 days prior to study entry or planning to receive an investigational drug during the study period
- •5.Previous treatment with Bimosiamose
- •6.Known allergy to any of the components of Bimosiamose 5% Cream
- •7.Cancerous or pre-cancerous lesions
- •8.Any condition which in the opinion of the investigator makes the patient unable to complete the study per protocol (e.g. patients not likely to stay in the study for 140 days because of other commitments, concomitant conditions, or past history; patients anticipated to be unreliable; or patients who have a concomitant condition that might confuse or confound study assessments)
- •9.Severe allergies manifested by a history of anaphylaxis or a history of multiple allergies
- •10.Receiving immunosuppressive therapy
- •11.Positive results on urine drug screen
- •12.Current signs of alcohol abuse
- •13.The patient has laboratory test results that indicates acute or chronic infectious hepatitis A, B or C or an infection with human immunodeficiency virus (HIV)
- •14.gamma-GT =3 times the upper limit of normal
- •15.Platelet count =10% below the lower limit of normal
- •16.Subject is institutionalized because of legal or regulatory order
研究者
相似试验
已完成
2 期
A clinical trial to study the effects of Bacillus subtilis strain PB6, as add-on to standard maintenance therapy in the treatment of mild to moderate ulcerative colitisCTRI/2009/091/000693Kemin Pharmaa division of Kemin Industries South Asia Pvt. Ltd.The Trapezium, No 39, Nelson Manickam Road, Chennai-600029, India
已完成
2 期
Multi-center, randomized, double-blind, placebo-controlled phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered BAY63-2521 in adult deltaF508 homozygous Cystic Fibrosis patientsmucoviscidosis1002766410010613NL-OMON42435Bayer HealthCare AG5
进行中（未招募）
1 期
Safety and tolerability of BAY63-2521 in Cystic Fibrosis patientsCystic FibrosisEUCTR2013-004595-35-NLBayer HealthCare AG40
进行中（未招募）
不适用
Multi-center, randomized, double-blind, placebo-controlled, cross-over Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-017257-35-DERevotar Biopharmaceuticals AG77
已完成
2 期
A placebo controlled clinical trial to evaluate safety and efficacy of two doses of AM 3301 for add-on treatment of mild to moderate active ulcerative colotisCTRI/2010/091/000444Kemin Pharma180